Letter Opposing a Proposed Low-dose Stavudine Trial
TAG and other partner organizations issued this letter about their serious and unresolved concerns about the proposed clinical trial comparing stavudine at 20 mg to tenofovir.
Strengthening the Role of the Stop TB Partnership in the Struggle Against Tuberculosis
A follow up to the letter of May 3, 2011, regarding the steps being taken by the Coordinating Board to reduce the conflict of interest in the Stop TB Partnership’s relationship with the World Health Organization (WHO), improve transparency and accountability in the operations and activities of the Partnership, and strengthen the Partnership’s ability to fulfill its mandate.
Congressman Stark Introduces Bill to Tax Big Banks for Global Health, Climate, Deficit
TAG and other faith, labor, environmental, health, education, and development organizations sent this letter to President Barack Obama urging him to support a miniscule tax on speculative financial transactions.
Steps being taken by the Coordinating Board to reduce conflict of interest and improve transparency in the Stop TB Partnership
Letter from TAG and other civil society organizations.
We CAN End the AIDS Epidemic
Letter from TAG and other signatories calling on all governments, donors, international agencies, researchers, implementers and civil society to act to end the AIDS epidemic now.
Letter to Secretary Clinton on the Global Fund to Fight AIDS, TB, and Malaria
February 7, 2011 Dear Secretary Clinton, We write to ask for your leadership in ensuring The Global Fund to Fight AIDS, TB, and Malaria is “open for new business,” saving lives through expanding programming in 2012. We ask that you…
Letter to Dr. Fauci to Support HIV and Aging Research
The many complications and comorbidities faced by the aging population of HIV positive people in the United States constitute a rapidly growing medical crisis that has been woefully neglected by U.S. research efforts.
Letter to David Kessler, US FDA
Dear Commissioner Kessler: We're writing with reference to FDA’s plans to regulate the development of a new class of anti- HIV therapies known as “protease inhibitors,” and with specific reference to possible regulatory decisions regarding Hoffmann-LaRoche, Inc.’s Ro 31-8959 (“saquinavir”).